Intellia Therapeutics, a Novartis-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA.
French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer a turnaround.
When Astellas signed a deal to acquire Ocata Therapeutics in November, it expected the company's shareholders to accept its $8.50-a-share offer within 20 days. But a group of jilted Ocata investors has refused to budge, agitating for a better return and forcing the Japanese drugmaker to prolong the process.
GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $72 million plus royalties.
In this week's Chutes and Ladders, Rohan Palekar was appointed CEO of Avanir Pharmaceuticals, Allan Shaw was named CFO at Syndax, and Dr. Craig Granowitz was named chief medical officer at Amarin. Plus more hirings and retirings throughout the industry.
XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D disappointments.
In this week's EuroBiotech Report, the first of two correctors destined for use in Galapagos' triple-hit cystic fibrosis therapy is now in the clinic. With as many as four more assets due to enter Phase I before 2016 is over, Galapagos thinks it has the credentials to call the franchise a full-sized portfolio. And more.
MannKind, decimated by the departure of former co-signer Sanofi, is trying to conserve value in the face of sluggish sales for its inhaled insulin, signing a deal to transfer some of its pipeline to an obscure new company.
Vasopharm has emerged from talks with investors armed with €20 million ($22 million) to hustle its treatment for traumatic brain injury through Phase III. The funding gives vasopharm renewed momentum after a period in which its lead candidate was stuck between trials for several years.
China's Cocoon rolls out a $720M fund to back U.K. biotechs; AbbVie teams up with MD Anderson on immuno-oncology;
The FDA is taking a snow day this Friday, abandoning scheduled plans to submit Sarepta's Duchenne muscular dystrophy drug to a review by outside experts.
Yu Xue had a hard-earned reputation as a top chemist while she was working for GlaxoSmithKline in its Upper Merion, PA, facility. But Yu Xue--better known as Joyce--was also an accomplished thief during the last four years of her 10-year tenure, according to allegations laid out in a federal indictment filed by the U.S. Attorney's office in Eastern Pennsylvania.
Alkermes reported this morning that its closely watched depression drug ALKS-5461 failed to hit the primary endpoints in the first two of three Phase III studies, slamming the company and the troubled field of depression drug research with a serious setback.
Over the past three months, Martin Shkreli rarely passed up an opportunity to publicly mock his critics or justify a 5000%-plus price hike on a 62-year-old generic. But when it comes to a Senate probe into the price hike, Shkreli is taking the 5th.
The international team at Abingworth likes investing in co-development programs, backing two companies that specialize in taking on the risk and cost of Phase III in exchange for a piece of a precalculated, multiyear payout that can be earned for success. And now it has its first, standalone fund stocked with $105 million to invest in more such pacts.
In the wake of a disastrous French clinical trial that left one volunteer dead, Johnson & Johnson has voluntarily suspended development of a similar drug until more information comes to light.
Galapagos has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) drug, GLPG2222. The start of the trial marks another milestone in the rolling advance of Galapagos' multipronged attack on CF, which is set to be bolstered later this year by the emergence of more next-generation correctors.
Federated Investors has bought an 8.6% stake in arGEN-X. The deal sees arGEN-X sell shares worth €16 million ($17.5 million) to the major U.S. asset manager, giving it additional financial firepower at a time when it is closing in on clinical proof-of-concept trials for a clutch of key drugs.
Bristol-Myers Squibb, working alongside CytomX Therapeutics, picked a third cancer project in a collaboration that could pay its partner as much as $1.2 billion.
Vice President Joe Biden used the spotlight at the World Economic Forum in Davos to gather together some of the top players in drug R&D and highlight his push to speed up the development and approval of new cancer drug combos. His message won the enthusiastic support of NIH chief Francis Collins and resonated with insiders at the FDA, a list that likely includes cancer drug czar Richard Pazdur, who's been playing a leading role in revamping the way cancer drugs are studied and approved for marketing over the past three years.